Media Coverage · February 12, 2018
Acticor Biotech annonce la fin de son étude clinique de phase I – Biotech finance [FR]
February 2018. Acticor Biotech annonce la fin de son étude clinique de phase I avec son candidat médicament ACT017. Cet essai a permis de valider …
Download full text article (PDF, French)
Read next in 'Media Coverage'
- ACT017 : un fragment d’anticorps dont l’ACTion antithrombotique est prometteuse !
- Novel antiplatelet could circumvent bleeding risk for stroke patients
- Experimental antiplatelet compound for acute stroke shows promise
- New drug to prevent clots clears safety hurdle
- New blood thinner may prevent stroke, without risk for bleeding